Thiazolidinediones, deadly sins, surrogates, and elephants

Lancet

Volumn 370, Issue 9593, 2007, Pages 1103-1104

  Cleland, John GF ^a   Atkin, Stephen L ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ARTICLE; DRUG EFFECT; DRUG SAFETY; ELEPHANT; GLYCEMIC CONTROL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS;

EID: 34648843711     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61488-3     Document Type: Note

References (11)

1. Nissen S., and Wolski K. Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
2. Home P., Pocock S., Beck-Nielsen H., and for the RECORD study group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 357 (2007) 28-38
3. Dormandy J., Charbonnel B., Eckland D., and on behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
4. Lago R., Singh P., and Nesto R. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (2007) 1129-1136
5. Cleland J., Coletta A., Nikitin N., and Clark A. Clinical trials update from the American College of Cardiology: Darbepoeitin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND. Eur J Heart Fail 8 (2006) 326-329
6. Dargie H., Hildebrandt P., Riegger G., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II heart failure. J Am Coll Cardiol 49 (2007) 1696-1704
7. Cleland J., Taylor J., and Tendera M. Prognostic value of measuring NT-proBNP in patients who appear to have heart failure due to diastolic left ventricular function. N Engl J Med 357 (2007) 829-830
8. Nissen S., Tardif J.-C., Nicholls S., and for the ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
9. Psaty B., Furberg C., Ray W., and Weiss N. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 292 (2004) 2622-2631
10. Carlberg B., Samuelsson O., and Lindholm L. Atenolol in hypertension: is it a wise choice?. Lancet 364 (2004) 1684-1689
11. Anand I., Florea V., and Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol 39 (2002) 1414-1421